Product Images Irinotecan Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 6 images provide visual information about the product associated with Irinotecan Hydrochloride NDC 45963-614 by Actavis Pharma, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
9a178e71-figure-01 - image 1
9a178e71-figure-02 - image 2
9a178e71-figure-03 - image 3
1 - image 4
image 5
This dataset includes information on the comparison between Irinotecan and 5-Fluorouracil (5-FU), with a sample size of 127 and 129 patients respectively. The median follow-up period is 15 months, with median survival rates of 108 months for Irinotecan and 85 months for 5-FU. The probability of survival for Irinotecan is reported as 0.44, with a p-value of 0.035 based on a log-rank test analysis.*
image 6
This is a product label for Irinotecan Hydrochloride Injection, USP. It provides information about the dosage (40 mg/2 ml), dilution requirement, and warnings for intravenous use only as it is a cytotoxic agent. The text also mentions that the vial stopper is sterile, non-pyrogenic, and preservative-free. The medication is manufactured in Romania and by Teva Pharmaceuticals. It is important to read the entire label before use and follow dosage and administration instructions provided in the package insert.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
